{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:40:04Z","timestamp":1746340804533,"version":"3.40.4"},"reference-count":21,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"51","license":[{"start":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T00:00:00Z","timestamp":1640217600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["no. 81803993"],"award-info":[{"award-number":["no. 81803993"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Methotrexate and leflunomide are classic treatments for rheumatoid arthritis (RA), however, which is the best choice for patients of RA is still an important question clinically, and this meta-analysis is used to systematically evaluate and compare their efficacy and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We searched PubMed, Cochrance Library, Embase, SinoMed, China National Knowledge Infrastructure, China Science and Technology Journal Database, WanFang Data databases. The retrieval time was from the establishment to September 7, 2021. Literature screening, data extraction, and quality assessment were performed according to the Cochrane risk of bias tool. Meta-analysis of the included studies was performed using RevMan 5.3 software and Stata 12.0 software.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The clinical efficacy and safety of leflunomide and methotrexate are evaluated by American College of Rheumatology (ACR)20\/50\/70, DAS28, total effective rate, adverse reaction rate, morning stiffness, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein, and rheumatoid factor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>The results of this meta-analysis will provide reliable evidence clinical efficacy and safety for RA. More high-quality randomized controlled trials are still needed to provide more reliable evidence for the treatment of RA.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>PROSPERO number:<\/jats:title>\n            <jats:p>CRD42021270980<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000028285","type":"journal-article","created":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T19:19:15Z","timestamp":1640287155000},"page":"e28285","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Clinical efficacy and safety of methotrexate compared with leflunomide in the treatment of rheumatoid arthritis"],"prefix":"10.1097","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7854-3943","authenticated-orcid":false,"given":"Weiyu","family":"Qi","sequence":"first","affiliation":[{"name":"Hunan University of Chinese Medicine, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Xia","sequence":"additional","affiliation":[{"name":"Hunan University of Chinese Medicine, Changsha, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[{"name":"Hunan University of Chinese Medicine, Changsha, China"},{"name":"Hunan Provincial Key Laboratory of Diagnostics in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianzhong","family":"Cao","sequence":"additional","affiliation":[{"name":"Hunan Provincial Key Laboratory of Diagnostics in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2021,12,23]]},"reference":[{"key":"R1-20250504","first-page":"360","article-title":"Therapeutic effect and mechanism of different Tripterygium wilfordii preparations on patients with rheumatoid arthritis accompanying anemia","volume":"36","author":"Sun","year":"2020","journal-title":"Chin J Immunol"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"445","DOI":"10.55563\/clinexprheumatol\/j1l5l3","article-title":"One year in review 2021: pathogenesis of rheumatoid arthritis","volume":"39","author":"Testa","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1517\/13543776.2015.1044972","article-title":"Analysis of patents on anti-rheumatoid arthritis therapies issued in China","volume":"25","author":"Yuan","year":"2015","journal-title":"Expert Opin Ther Pat"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"R5-20250504","first-page":"242","article-title":"2018 Chinese guideline for the diagnosis and treatment of rheumatoid arthritis","volume":"57","year":"2018","journal-title":"Chin J Internal Med"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ejmech.2018.09.027","article-title":"Side effects of methotrexate therapy for rheumatoid arthritis: a systematic review","volume":"158","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"R7-20250504","first-page":"1906","article-title":"Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD","volume":"31","author":"Cannon","year":"2004","journal-title":"J Rheumatol"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"R9-20250504","first-page":"g7647","article-title":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation","volume":"349","author":"Shamseer","year":"2015","journal-title":"BMJ Clin Res"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.dmpk.2019.08.003","article-title":"Investigation on inhibitory effect of folic acid on methotrexate-induced epithelial-mesenchymal transition focusing on dihydrofolate reductase","volume":"34","author":"Kawami","year":"2019","journal-title":"Drug Metab Pharmacokinet"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"09","DOI":"10.1016\/j.biochi.2020.03.014","article-title":"Regulatory T cells in patients with early untreated rheumatoid arthritis: phenotypic changes in the course of methotrexate treatment","volume":"174","author":"Avdeeva","year":"2020","journal-title":"Biochimie"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/jcm8111859","article-title":"Methotrexate restores CD73 expression on Th1.17 in rheumatoid arthritis and psoriatic arthritis patients and may contribute to its anti-inflammatory effect through ado production","volume":"8","author":"Bossennec","year":"2019","journal-title":"J Clin Med"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.2217\/pgs-2019-0121","article-title":"Methotrexate pharmacogenetics in the treatment of rheumatoid arthritis","volume":"20","author":"Jekic","year":"2019","journal-title":"Pharmacogenomics"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1007\/s00774-015-0702-2","article-title":"Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors","volume":"34","author":"Kanagawa","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1517\/14740338.2013.798299","article-title":"Safety evaluation of leflunomide in rheumatoid arthritis","volume":"12","author":"Keen","year":"2013","journal-title":"Expert Opin Drug Saf"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cyto.2005.06.002","article-title":"Effects of the active metabolite of leflunomide, A77 1726, on cytokine release and the MAPK signalling pathway in human rheumatoid arthritis synoviocytes","volume":"31","author":"Vergne-Salle","year":"2005","journal-title":"Cytokine"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1038\/s41467-019-12163-z","article-title":"HIF1alpha inhibition facilitates leflunomide-AHR-CRP signaling to attenuate bone erosion in CRP-aberrant rheumatoid arthritis","volume":"10","author":"Liang","year":"2019","journal-title":"Nat Commun"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cyto.2005.12.009","article-title":"The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis","volume":"33","author":"Litinsky","year":"2006","journal-title":"Cytokine"},{"key":"R19-20250504","first-page":"155","article-title":"Inhibitory effects of leflunomide therapy on the activity of matrixmetalloproteinase-9 and the release of cartilage oligomeric matrix protein in patients with rheumatoid arthritis","volume":"24","author":"Kullich","year":"2006","journal-title":"Clin Exp Rheumatol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.2133\/dmpk.DMPK-13-RV-119","article-title":"Molecular basis for pharmacokinetics and pharmacodynamics of methotrexate in rheumatoid arthritis therapy","volume":"29","author":"Inoue","year":"2014","journal-title":"Drug Metab Pharmacokinet"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1365-2125.2005.02415.x","article-title":"Population pharmacokinetics and association between A77 1726 plasma concentrations and disease activity measures following administration of leflunomide to people with rheumatoid arthritis","volume":"60","author":"Chan","year":"2005","journal-title":"Br J Clin Pharmacol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028285","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T06:08:12Z","timestamp":1746338892000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000028285"}},"subtitle":["A protocol for systematic review and meta-analysis"],"short-title":[],"issued":{"date-parts":[[2021,12,23]]},"references-count":21,"journal-issue":{"issue":"51","published-online":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000028285","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2021,12,23]]},"assertion":[{"value":"2021-11-23","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-29","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}